Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Duchenne Muscular Dystrophy clinical trials

Directory of U.S. ClinicalTrials.gov public records for Duchenne Muscular Dystrophy. Browse Duchenne Muscular Dystrophy recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
237
Shown on this page
12
Current sort
Recently updated
Condition scope
Duchenne Muscular Dystrophy
Additional filters apply within this condition.
The trial list below is retrieved from the live ClinicalTrials.gov search API for Duchenne Muscular Dystrophy. Results on this page are currently sorted by Recently updated.

How Duchenne Muscular Dystrophy studies are organized in the registry

Duchenne records are often titled with just “Duchenne” or the abbreviation DMD, and much of the portfolio is organized around a therapeutic platform — gene transfer, exon skipping — which appears in titles. Because Duchenne is diagnosed in childhood, the age filter meaningfully changes what you see.

Terms that often appear in related listings
DMD exon skipping gene therapy ambulatory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Duchenne Muscular Dystrophy. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1–12 of 237 matching trials for Duchenne Muscular Dystrophy.
Live ClinicalTrials.gov results.
Active filters: "DMD" Clear condition filters
Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search
Recruiting No phase listed Observational

Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

NCT06564974
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Vamorolone
Drug
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Open-label Extension of the HOPE-2 Trial

NCT04428476
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Deramiocel (CAP-1002)
Biological
Lead sponsor
Capricor Inc.
Industry
Eligibility
10 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
Sacramento, California • Aurora, Colorado • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)

NCT05291091
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten 10 mg, Sevasemten 5 mg, Sevasemten 12.5 mg, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
12 Years to 50 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101

NCT06867107
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
SAT-3247
Drug
Lead sponsor
Satellos Bioscience, Inc.
Industry
Eligibility
16 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Columbus, Ohio • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

NCT07287189
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Interventions
SAT-3247, Placebo
Drug
Lead sponsor
Satellos Bioscience, Inc.
Industry
Eligibility
7 Years to 9 Years · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Enrolling by invitation Phase 2 Interventional

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

NCT06066580
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Sevasemten
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
24
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

NCT06817382
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
INS1201
Genetic
Lead sponsor
Insmed Gene Therapy LLC
Industry
Eligibility
2 Years to 4 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Little Rock, Arkansas • Davis, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT05996003
View directory record Official record
Conditions
Duchenne Muscular Dystrophy, Exon 44, DMD
Interventions
NS-089/NCNP-02
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 14 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

NCT05166109
View directory record Official record
Conditions
Becker Muscular Dystrophy
Interventions
Vamorolone, Placebo
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Recruiting Phase 1 Interventional

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

NCT04626674
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
2 Years and older · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
12
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

NCT06450639
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Satralizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
8 Years to 17 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Little Rock, Arkansas • Sacramento, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 25, 2026, 4:56 PM EDT
Active, not recruiting No phase listed Observational

Defining Endpoints in Becker Muscular Dystrophy

NCT05257473
View directory record Official record
Conditions
Becker Muscular Dystrophy, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Becker
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 4:56 PM EDT

About this Duchenne Muscular Dystrophy clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Duchenne Muscular Dystrophy as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Duchenne Muscular Dystrophy.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Duchenne Muscular Dystrophy.